Freely Filtered, a NephJC Podcast
Health & Fitness:Medicine
The Filtrate:
Joel Topf
Swapnil Hiremath
Sophia Ambruso
AC Gomez
Josh Waitzman
Jennie Lin
Nayan Arora
The Curbsiders
Matt F. Watto (@DoctorWatto)
Paul Nelson Williams, America’s primary care physician (@PaulNWilliamz)
With Special Guest:
JD Foster (@KidneyVet)
Sayed Tabatabai (@TheRealDoctorT) Nephrologist in Austin and the author of These Vital Signs
Michelle Rheault (@rheault_m) Chief of Pediatric Nephrology at the University of Minnesota and lead author of the DUPLEX Trial
Editor:
Joel Topf
Show Notes:
Lily toxicity in the cat (PubMed)
Surgeons perform kidney transplants in cats amid rising demand for advanced pet care (ABC News)
Treatment of ibuprofen toxicity with serial charcoal hemoperfusion and hemodialysis in a dog (PubMed)
Nephrology in Veterinary Medicine (Kidney 360)
Star Wars Society of San Antonio (FaceBook)
These Vital Signs (Amazon)
Dr Tabatabai read a short story called The Handholder, here is the original tweet thread for that story (ThreadReader)
The pearl not the patient (PubMed)
Late Braking and High Impact Clinical Trial press release
MENTOR, Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy, was in 2019 not 2017 (NEJM)
KALM-1, A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus, was in 2019 not 2017 (NEJM)
Sophie’s number one pick: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (Lancet)
Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058).
Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration (AJKD)
AC Gomez’s Pick: MDR-101-MLK Update: Operational Immune Tolerance Achieved in Living Related HLA-Matched Kidney Transplant Recipients (ASN-Online.org)
Josh’s Pick: A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (NEJM)
Nayan’s Pick: The EnAKT LKD Cluster Randomized Clinical Trial (JAMA Internal Medicine)
The Freely Filtered simultaneous release (NephJC)
Freely Filtered is now a verb.
Swap’s Pick: Strategies for the Management of Atrial Fibrillation in PatiEnts Receiving Dialysis (SAFE-D) (ASN-Online.org)
Joel’s Pick: AYAME Study: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Bardoxolone Methyl in Diabetic Kidney Disease (DKD) Patients (ASN-Online.org)
Reata is a no-show to the 2012 ASN Kidney Week (PBFluids)
Michelle’s Pick: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. The DUPLEX Study (NEJM)
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS (PubMed)
Freely Filtered 053: The Kidney Week Draft
Freely Filtered 052: Acetazolamide for Acute Decompensated Heart Failure (ADVOR)
Freely Filtered 051: Pip Tazo and Vanco: Nephrotoxin or Not so toxic
Freely Filtered 050: CLASSIC Trial
Freely Filtered 049: Getting Salty with SODIUM-HF
Freely Filtered 048: Putting TESTING to the Test
Freely Filtered 047: CHAP, time to treat hypertension in pregnancy
Freely Filtered 046: The ISPD Peritonitis Guideline Draft
Freely Filtered 045: Salt Substitution and Stroke Study (SSaSS)
Freely Filtered 044: Pigs on the Wing: Xenotransplantation
Freely Filtered 043: NephMadness and Animal House
Freely Filtered 042: Nephrin Antibodies Cause Minimal Change Disease. Wait...What?
Freely Filtered 041: Top Nephrology Stories of 2021
Freely Filtered 040: Double CLICK for BP control in CKD stage 4
Freely Filtered 039: The First Annual ASN #KidneyWk Draft
Freely Filtered 038: AURORA1, a new treatment for Lupus Nephritis
Freely Filtered 037: The first Guideline Draft: KDIGO Hypertension Guidelines
Freely Filtered 036: AKIKI-2, How soon is now?
Freely Filtered 035: ASN Fellow Survey, COVID-19 Edition
Freely Filtered 034: Terlipressin for Hepatorenal Syndrome
Create your
podcast in
minutes
It is Free
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
URGENŤÁCI